Indication: Peds Onc

ADVL1823, Larotrectinib (LOXO-101, NSC#788607, IND#141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias

Sub-indication: Leukemia

Study Type: Drug Study

Principal Investigator: Ashok Raj, M.D.
Norton Children's Cancer Institute, affiliated with the UofL School of Medicine

Sponsor: Sponsor: Children's Oncology Group (COG)

Learn more at ClinicalTrials.gov

Email for more information: NCRI-Cancer@NortonHealthcare.org

Search our entire site.